Drug General Information
Drug ID	D08PMB
Former ID	DIB006278
Drug Name	Imeglimin
Drug Type	Small molecular drug
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 2	[524449]
Company	Merck KGaA
Structure		Download 2D MOL 3D MOL
Formula	C6H13N5
Canonical SMILES	N1=C(N[C@@H](N=C1N)C)N(C)C
CAS Number	CAS 775351-65-0
PubChem Compound ID	24812808
Target and Pathway
Target(s)	AMP-activated protein kinase	Target Info	Modulator	[549117]
KEGG Pathway	FoxO signaling pathway
	Regulation of autophagy
	mTOR signaling pathway
	PI3K-Akt signaling pathway
	AMPK signaling pathway
	Circadian rhythm
	Insulin signaling pathway
	Adipocytokine signaling pathway
	Oxytocin signaling pathway
	Glucagon signaling pathway
	Non-alcoholic fatty liver disease (NAFLD)
	Hypertrophic cardiomyopathy (HCM)
Reactome	Translocation of GLUT4 to the plasma membrane
	Macroautophagy
	Activation of PPARGC1A (PGC-1alpha) by phosphorylation
	TP53 Regulates Metabolic Genes
WikiPathways	Insulin Signaling
	Energy dependent regulation of mTOR by LKB1-AMPK
	JAK/STAT
	BDNF signaling pathway
	Leptin signaling pathway
	SREBF and miR33 in cholesterol and lipid homeostasis
	SREBP signalling
	Signaling by Insulin receptor
	TOR Signaling
	AMPK Signaling
References
Ref 524449	ClinicalTrials.gov (NCT01951235) A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 549117	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.